Table 1. Patient characteristics.
| Patients ( n = 54) | |
|---|---|
| Age at CTEPH diagnosis (y, SD) | 63 (15) |
| Male sex ( n , %) | 26 (48) |
| mPAP at diagnosis of CTEPH (average mm Hg, SD) | 42 (12) |
| Number of VTE events (median, IQR) | 1 (1–2) |
| Treatment of last PE | |
| Vitamin K antagonist ( n , %) | 48 (89) |
| DOAC ( n , %) | 6 (11) |
| Duration of last PE to CTEPH diagnosis (median months, IQR) | 9 (5–15) |
| Comorbidities at the moment of CTEPH diagnostic workup | |
| COPD ( n , %) | 11 (20) |
| Chronic left heart failure ( n , %) | 1 (2) |
| Rheumatic diseases ( n , %) | 7 (13) |
| Malignancy ( n , %) | 8 (15) |
| Splenectomy ( n , %) | 2 (4) |
| Prior infected pace maker lead ( n , %) | 0 |
| Known antiphospholipid syndrome ( n , %) | 2 (4) |
Abbreviations: COPD, chronic obstructive pulmonary disease; CTEPH, chronic thromboembolic pulmonary hypertension; DOAC, direct oral anticoagulants; IQR, interquartile range; mPAP, mean pulmonary artery pressure; PE, pulmonary embolism; SD, standard deviation; VTE, venous thromboembolism.